Homocystinuria, the vitamin-responsive amino acid disorder

The textbook clinical picture of untreated classical homocystinuria includes intellectual disability, marfanoid habitus, dislocated lenses, premature thromboembolic events, and accelerated atherosclerosis. The textbook treatment, started in infancy, prevents most of it. The condition is one of the small number on the newborn screening panel where a single vitamin pyridoxine, given at sufficient dose to a responsive child, can substantially correct the underlying metabolic block. For non-responsive cases, methionine restriction, betaine, and folate fill in.

What homocystinuria is

Classical homocystinuria is an autosomal recessive disorder of methionine catabolism. The enzyme cystathionine beta-synthase, CBS, encoded by CBS on chromosome 21q22, condenses homocysteine with serine to form cystathionine, the first committed step of the trans-sulfuration pathway. Pathogenic variants in CBS reduce or abolish enzyme activity. Homocysteine and methionine accumulate in blood and tissues. Disulfide bond chemistry, fibrillin metabolism, and one-carbon metabolism are all affected, and the clinical consequences appear in connective tissue, the eye, the central nervous system, and the vasculature.

The classical phenotype includes ectopia lentis (downward dislocation of the lenses, classically), a marfanoid habitus with tall stature and long limbs, osteoporosis, intellectual disability of variable severity, psychiatric features, and a strong predisposition to thromboembolic events including stroke and pulmonary embolism in young adults. Vascular events can occur in childhood. The lens dislocation is often the first clinical finding to bring an unscreened child to medical attention.

A subset of CBS variants are pyridoxine-responsive. Pyridoxine, vitamin B6, is the cofactor of CBS. In pyridoxine-responsive cases, supraphysiological doses of B6 partially restore enzyme activity and reduce homocysteine accumulation. The biochemical and clinical responsiveness is determined by the specific variant. Roughly half of CBS-deficient cases are pyridoxine-responsive in pharmacological doses.

A separate group of homocystinurias arises from defects in the remethylation pathway, which converts homocysteine back to methionine. Cobalamin (B12) defects, methionine synthase deficiency, and MTHFR deficiency produce homocystinuria with low or normal methionine, in contrast with the elevated methionine of classical CBS deficiency. The remethylation defects have a different clinical course and a different management approach.

Detection

Newborn screening for homocystinuria uses methionine on the dried blood spot, with second-tier testing including total plasma homocysteine measurement and CBS sequencing. Methionine elevation is the screening marker for classical CBS deficiency. The remethylation defects are not always reliably detected by methionine alone because methionine in those forms is normal or low; some programs include propionylcarnitine or other markers as second-tier flags for the cobalamin-related forms.

Reported live-birth incidence of classical homocystinuria in unselected screening programs runs roughly 1 in 200,000 to 1 in 350,000. Founder effects produce higher rates in specific regions, including parts of Ireland and Qatar.

What management looks like

Standard of care depends on pyridoxine responsiveness.

For pyridoxine-responsive cases, oral pyridoxine at pharmacological doses, typically 100 to 500 mg per day or higher in adults, normalizes or substantially reduces homocysteine. Folate, methylcobalamin, and modest dietary measures complete the regimen. Children identified by screening and started on B6 in the first weeks of life have substantially preserved cognitive outcomes and reduced thromboembolic risk compared with cases diagnosed clinically.

For pyridoxine-non-responsive cases, treatment combines a methionine-restricted diet using medical formula free of methionine combined with measured natural protein, betaine (Cystadane, FDA-approved 1996), and folate. Betaine donates a methyl group that allows alternative remethylation of homocysteine to methionine through betaine-homocysteine methyltransferase, reducing homocysteine accumulation. The diet plus betaine combination requires lifelong adherence and metabolic dietitian supervision.

Pegtibatinase, an enzyme replacement therapy delivering a pegylated recombinant CBS, was in late-stage clinical trials in 2024 for pyridoxine-non-responsive classical homocystinuria. The therapy is intended to address the substantial residual disease burden in non-responsive cases despite optimal diet and betaine.

Surveillance includes ophthalmology evaluation for lens dislocation, bone density assessment, and cardiovascular risk reduction including avoidance of estrogen-containing contraceptives where alternative methods are appropriate, given the elevated thromboembolic risk in classical homocystinuria. Pre-operative homocysteine optimization is important because perioperative thromboembolic events are documented in the literature.

Outcomes after screening

Universal newborn screening shifted the outcomes of classical homocystinuria substantially in countries that implemented it early. Pyridoxine-responsive cases identified at birth and started on B6 in the first weeks of life rarely develop the textbook clinical picture. Pyridoxine-non-responsive cases identified at birth and started on diet plus betaine have measurably lower rates of intellectual disability, lens dislocation, and thromboembolic events than clinically diagnosed cohorts of the pre-screening era.

The condition is on the newborn screening panel of every US state and most high-income economies. Methionine-based screens differ in their sensitivity for the various subtypes of homocystinuria, and detection of the remethylation defects is incomplete in some programs.

What this looks like for a family

A baby is born and the heel-prick is sent. The state lab reports an elevated methionine. Confirmatory testing returns elevated total plasma homocysteine and biallelic CBS variants. The metabolic team takes a pyridoxine challenge to assess responsiveness. The child responds. Pyridoxine, folate, and B12 supplementation begin. The metabolic dietitian provides a moderate protein-restriction plan as a backup.

The child grows up with regular metabolic clinic visits, periodic ophthalmologic checks, and a consistent oral medication routine. The lens dislocation that would have brought the child to a pediatric ophthalmologist at age 6 in the unscreened pre-1990s era never develops. The stroke that would have happened at age 25 in an untreated cohort never happens.

That is what homocystinuria care looks like, in practice, when the screen catches it early and the variant happens to respond to the vitamin.